GC Green Cross Wellbeing Successfully Holds OnePrep 1.38 Acid General Hospital Roundtable

GC Green Cross Wellbeing announced on August 4 that it held a 'OnePrep 1.38 Acid General Hospital Roundtable' together with Geongangyakpum and the InterContinental Hotel on July 26.

From the left in the photo, Professor Youngseok Cho of Seoul St. Mary's Hospital, Professor Yuseon Kim of Kangdong Sacred Heart Hospital, Professor Jiwon Kim of Seoul Metropolitan Boramae Hospital, and Professor Jongpil Lim of Seoul National University Hospital are taking a commemorative photo. Photo by Yonhap News

This roundtable was chaired by Professor Kim Ji-won of Seoul Boramae Hospital and brought together gastroenterology specialists to discuss the latest insights on bowel cleansing agents and 'OnePrep 1.38 Acid'.

The detailed sessions included: ▲ Latest insights and guidelines on bowel cleansing agents and a review of same-day bowel preparations (Professor Lim Jong-pil, Seoul National University Hospital); ▲ Post-marketing surveillance results and comparison of phase 3 clinical trial outcomes for OnePrep 1.38 Acid (Professor Cho Young-seok, Seoul St. Mary's Hospital, Catholic University); ▲ Review of the latest tablet-type bowel cleansing agents using sulfate as the main ingredient (Professor Kim Yoo-sun, Kangdong Sacred Heart Hospital).

Professor Kim Ji-won (Seoul Boramae Hospital), who chaired the event, stated, "Recently, there has been a growing demand among patients to undergo colonoscopy using low-dose medication on the day of the examination. It was a meaningful occasion to share opinions on safely and conveniently performing colonoscopy by prescribing appropriate bowel cleansing agents tailored to the patient's characteristics and underlying conditions."

Professor Lim Jong-pil (Seoul National University Hospital) said, "The 2019 European Society of Gastrointestinal Endoscopy (ESGE) guidelines recommend same-day dosing for afternoon endoscopies. A regimen of taking 1.38L without intervals within one hour on the same day may enhance patient convenience."

Professor Cho Young-seok (Seoul St. Mary's Hospital, Catholic University) commented, "In post-marketing surveillance conducted from 2020 to the present, the efficacy rate was 96.7% among 639 subjects, which is similar to the 98.4% confirmed in phase 3 clinical trials. Given that safety for elderly patients is a key feature of bowel cleansing agents, among 224 cases aged 60 to under 80, 33 subjects (14.7%) experienced adverse events."

Professor Kim Yoo-sun (Kangdong Sacred Heart Hospital) added, "Recently, several tablet-type bowel cleansing agents with sulfate as the main ingredient have been launched. Providing a 1.38L low-volume bowel cleansing option may serve as an alternative for patients who have difficulty taking pills."

'OnePrep 1.38 Acid' is an improved new drug jointly marketed by GC Green Cross Wellbeing and Geongangyakpum since 2020. Compared to existing bowel cleansing agents, it features ▲ improved flavor (lemon flavor), ▲ minimum dosage (1.38L including water), and ▲ reduced dosing frequency (single dose in the morning of the examination day without prior-day dosing).

Han Jeong-yeop, Head of the IP Division at GC Green Cross Wellbeing, stated, "At this roundtable, we presented the post-marketing surveillance results and phase 3 clinical outcomes for 'OnePrep 1.38 Acid.' Through this presentation, we believe that 'OnePrep 1.38 Acid' will be positively evaluated by many medical professionals as a drug that can contribute to colorectal cancer prevention through colonoscopy."

This content was produced with the assistance of AI translation services.